Clinical Trials Browser

INDUSTRY × Cyclophosphamide × CNS × Clear all

Glioblastoma, Glioma

NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1 Active not recruiting

71 enrolled

CNS

Epilepsy, Neuroblastoma

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07502287 2026-03-30

DUAL-NK-NB

Phase 1/2 Recruiting

36 enrolled

CNS

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT07480941 2026-03-18

DUAL-CAR-NK-GB

Phase 1 Recruiting

36 enrolled

CNS

Glioblastoma, Glioma

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1 Terminated

40 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

248 enrolled

CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

84 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03709680 2025-01-14

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 2 Active not recruiting

128 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Bone Neoplasms, Medulloblastoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdoid Tumor

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2 Not yet recruiting

28 enrolled

CNS

Glioma

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Phase 1 Completed

81 enrolled

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1 Terminated

4 enrolled 8 charts

CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

NCT01403285 2014-05-19

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Phase 1 Terminated

6 enrolled

CNS

Glioblastoma

Clinical Trials

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

SELECT-2CAR

DUAL-NK-NB

DUAL-CAR-NK-GB

9-ING-41 in Pediatric Patients With Refractory Malignancies.

DALY II USA/ MB-CART2019.1 for DLBCL

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma